Showing 231-240 of 345 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Interferons and the Integrated Stress Response: Converging Pathways in β Cell Dysfunction in Type 1 Diabetes | The University of Chicago | Charanya Muralidharan | Cures | 01-March-2026 to 28-February-2029 | $285,000.00 |
| Investigating the role of integrated stress response in type 1 diabetes | The University of Chicago | Charanya Muralidharan | Cures | 01-March-2023 to 28-February-2026 | $209,066.00 |
| Dissecting HLA Mechanisms in T1D, SLE, and MS Through High-Throughput Self-Antigen Profiling | The University of Chicago | Aly Khan | Cures | 01-September-2025 to 31-August-2026 | $150,000.00 |
| Role of β-cell Golgi dysfunction in Type 1 diabetes pathogenesis | The University of Iowa | Samuel Stephens | Cures | 01-June-2024 to 31-May-2027 | $750,000.00 |
| Engineering B Cell–Targeted Microparticles to Induce Regulatory Immunity in Type 1 Diabetes | The University of North Carolina at Chapel Hill | Kristy Ainslie | Cures | 01-April-2026 to 31-March-2027 | $200,000.00 |
| The Development of 3-β-hydroxybutyrate binding protein based electrochemical micro-sensor and its application for CKM system | The University of North Carolina at Chapel Hill | Koji Sode | Improving Lives | 01-October-2022 to 30-September-2026 | $799,999.96 |
| GABP regulation of human beta cell proliferation | The University of Texas Health Science Center at Houston | Richard Cox | Cures | 01-September-2024 to 31-August-2026 | $200,000.00 |
| Development of Low Cost, High Precision Nano Pumps for Insulin Delivery | Torramics Inc. | Sergey Gimelshein | Improving Lives | 01-March-2023 to 31-August-2026 | $1,493,212.43 |
| Determining the role of SSTR2 on PRL-2903-mediated glucagon secretion | Trustees of Columbia University in the City of New York | Xiaojuan Chen | Improving Lives | 01-April-2026 to 31-March-2027 | $199,999.39 |
| In vivo analysis of human islet graft infiltration and its immunomodulation by antigen-specific therapy | Trustees of Columbia University in the City of New York | Remi Creusot | Cures | 01-August-2022 to 31-July-2025 | $699,995.75 |